Direct Maxillary Sinus Lift for Single Tooth Implant: A Clinical Study

Purpose: The aim of the study is to evaluate clinically and radiographically the long-term success of one-stage direct (lateral) sinus lift procedure using alloplastic bone graft material and bio-absorbable membrane in conjunction with two stage implant placement in atrophic partially edentulous posterior maxilla. Materials and methods: One stage direct maxillary sinus lift in conjunction with two stage implant placement was carried out in 10 patients at 11 sites. All the patients were partially edentulous with posterior maxillary alveolar ridge height of > 5 mm and were in the age group of 20 to 50 years. Bioactive glass putty, bio-absorbable collagen membrane and 3.75 × 11.5 mm implants were used. Patients were evaluated clinically and radio-graphically for 18 months after placement of implants at intervals of 6 months to assess increase in residual ridge height, peri-implant condition (marginal bone loss, plaque and gingival index) and implant stability. Results: Maxillary first molar was the most common site (72.72%) for sinus lift and implant placement. Caries was the most common cause (90.90%) for loss of tooth. Increase in residual ridge height ranged from (71.43-133.33%) as measured by Denta-Scan. Implant survival rate was 100%. Marginal bone loss ranged from (0.6-1.2 mm). Implant stability was measured by periotest (–2 to –6). Only one patient had perforation of sinus membrane, but it was sealed satisfactorily by bio-absorable membrane. Conclusion: One stage lateral sinus lift procedure with alloplastic bone graft material in combination with 2 stage implant placement has a predictable outcome in patients with severe resorption of posterior maxilla

Development and Validation of Analytical methods for estimation of Simvastatin and Fenofibrate

The present work describes Stability indicating RP-HPLC and First order derivative UV spectrophotometric method for the quantitative determination of Simvastatin and Fenofibrate. Materials and methods: The parameters Specificity, linearity, accuracy, precision, detection limit, quantitation limit, Robustness and system suitability tests were studied and their results were compiled to ICH guideline Q2 (R2).  Chromatography was carried out by reverse phase technique on an RP-18 with mobile phase composed of Acetonitrile: Water (90:10; %v/v) adjusted to pH 3.3 with 10% orthophosphoric acid) with flow rate 1 ml/min. Both drugs were eluted, isocratically using detection wavelength 230 nm. Methanol was used as a solvent, the spectrum was recorded between 200-400 nm wavelengths, and all the zero-order spectrum (D0) were converted to first-order derivative spectrum (D1) using delta lambda 2.0 and scaling factor 4. 240 nm (zero crossing point of Fenofibrate) and 306 nm (zero crossing point of Simvastatin) were used for determination of Simvastatin and Fenofibrate, respectively. Regression analysis of UV-Spectrophotometric method showed good linearity r2 = 0.9991 at 240 nm of Simvastatin 1-5 µg/ml and r2 = 0.9998 at 306 nm of Fenofibrate 10-50 µg/ml. For proposed methods, the linearity for both methods were obtained in the concentration range of 1-5 μg/ml for Simvastatin and 10-50 μg/ml for Fenofibrate. Statistical analysis by student’s t-test showed no significance difference between the results obtained by these two methods.  Results: The suitability of method for the quantitative determination of Simvastatin and Fenofibrate was proved by validation. Conclusion: The proposed methods and its results had been successfully applied and validated statistically to the simultaneous estimation of Simvastatin and Fenofibrate in their combination for quality analysi